Reply STOP to end or HELP for help
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimers disease: a preliminary investigation
New medications are also in the pipeline, which could increase competition and lower prices
The US Food and Drug Administration approved Bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD) in 2019
Two major caveats here: First, this was an observational study, not a randomized trial
Eur J Pharmacol 15(771):211219 Belosic Halle Z, Vlainic J, Drmic D, Strinic D, Luetic K, Sucic M et al (2017) Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine